Hemostatic Disorders  >>  vatreptacog alfa (NN 1731)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vatreptacog alfa (NN 1731) / Novo Nordisk
NCT00822185: Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers

Completed
1
32
Japan
vatreptacog alfa (activated), placebo
Novo Nordisk A/S
Congenital Bleeding Disorder, Healthy
07/09
07/09

Download Options